Peptides for Chronic Wounds That Won't Close
Peptide Wound Healing
95%
wound closure by day 12 with a dimeric GHK-Cu peptide hydrogel in infected wound models, versus 65% in controls.
Nature Communications, 2025
Nature Communications, 2025
View as imageA wound becomes chronic when the normal healing cascade stalls. In acute wounds, the process follows a predictable sequence: hemostasis, inflammation, proliferation, and remodeling. Chronic wounds, defined as wounds that fail to progress through these phases within 4-6 weeks, remain stuck in a prolonged inflammatory state. Diabetic foot ulcers, venous leg ulcers, and pressure injuries collectively affect an estimated 6.5 million patients in the United States alone, with annual treatment costs exceeding $25 billion. Standard wound care (debridement, moist dressings, offloading, compression) addresses the environment but does not directly restart the stalled molecular machinery. Peptide-based therapies target this gap by delivering signals that push wound biology forward: stimulating collagen synthesis, recruiting progenitor cells, promoting angiogenesis, and clearing infection. For the broader context of peptide wound dressings, see Peptide-Based Wound Dressings: The Next Generation of Bandages.
Key Takeaways
- GHK-Cu stimulated collagen synthesis 70% above baseline in fibroblast cultures (Maquart et al., 1988) and a dimeric GHK-Cu hydrogel achieved 95% wound closure by day 12 in infected wound models
- BPC-157 cream improved burn wound healing in mice even under corticosteroid impairment that normally prevents healing (Sikiric et al., 2003)
- Thymosin beta-4 accelerated wound repair in both diabetic (db/db) and aged mice, with significantly increased wound contracture and collagen deposition
- Granexin (αCT1), a connexin 43 mimetic peptide, reached phase III trials for diabetic foot ulcers after showing improved scar remodeling in earlier studies (Montgomery et al., 2021)
- Antimicrobial peptide hydrogels combine infection control and wound healing in a single application, addressing the two main reasons chronic wounds stall
- None of these peptides have achieved FDA approval for chronic wound healing as standalone therapies, though Granexin is the closest to market
Why Chronic Wounds Get Stuck
Chronic wounds share a common pathophysiology regardless of their cause. The inflammatory phase, which normally resolves within days, persists for weeks or months. Neutrophils and macrophages remain activated, continuously releasing reactive oxygen species and matrix metalloproteinases (MMPs) that degrade the extracellular matrix as fast as fibroblasts can build it. Growth factors like PDGF, EGF, and VEGF are either deficient or degraded by the excessive protease activity.
In diabetic wounds specifically, hyperglycemia impairs neutrophil and macrophage function, reduces nitric oxide production (which drives angiogenesis), and promotes advanced glycation end-products (AGEs) that stiffen the extracellular matrix. The result is a wound that cannot transition from inflammation to proliferation.
Peptide therapies can intervene at multiple points in this stalled cascade: promoting fibroblast migration and collagen synthesis (GHK-Cu), recruiting stem and progenitor cells (thymosin beta-4), stimulating angiogenesis (BPC-157), modulating the inflammatory-to-proliferative transition (connexin peptides), and clearing the biofilm infections that maintain inflammation (antimicrobial peptides).
GHK-Cu: The Copper Peptide with Decades of Wound Data
Glycyl-L-histidyl-L-lysine copper complex (GHK-Cu) is an endogenous tripeptide that circulates in human plasma. Its concentration declines with age, from approximately 200 ng/mL at age 20 to 80 ng/mL by age 60.
Maquart et al. (1988) published the foundational wound healing study, showing that GHK-Cu stimulated collagen synthesis in fibroblast cultures approximately 70% above baseline.[1] Wegrowski et al. (1992) demonstrated that GHK-Cu also stimulated sulfated glycosaminoglycan synthesis, the other major component of the extracellular matrix needed for wound repair.[2] Maquart et al. (1993) then confirmed in vivo effects, showing that GHK-Cu stimulated connective tissue accumulation in subcutaneously implanted sponges in rats.[3]
Buffoni et al. (1995) demonstrated that the tripeptide-copper complex enhanced wound healing processes and cultured fibroblast activity, while Arul et al. (2005) developed a biotinylated GHK peptide incorporated into a collagenous matrix as a biomaterial specifically for dermal wound healing, showing improved healing outcomes in animal models.[4][5]
In 2025, a Nature Communications study reported that a dimeric copper peptide hydrogel achieved approximately 95% wound closure by day 12 in infected wound models compared to 65% in controls, primarily through promoting neovascularization and tissue regeneration. The dimeric design doubled the copper-binding capacity, enhancing both the antimicrobial and pro-angiogenic effects.
For the full GHK-Cu profile, see GHK-Cu in Wound Repair: The Copper Peptide's Healing Properties.
BPC-157: The Gastric Pentadecapeptide in Wound Models
BPC-157 (Body Protection Compound-157) is a 15-amino acid synthetic peptide derived from a sequence in human gastric juice. Its wound healing research spans burn wounds, corneal defects, fistulas, and corticosteroid-impaired healing.
Sikiric et al. (1999) showed that BPC-157 promoted new vessel formation and new granulation tissue formation in wound models, linking the peptide's healing effects to angiogenesis.[6] Mikus et al. (2001) demonstrated that BPC-157 cream formulation improved burn wound healing in mice while simultaneously attenuating burn-induced gastric lesions, suggesting systemic protective effects beyond the application site.[7]
Sikiric et al. (2003) tested BPC-157 under the most challenging conditions: corticosteroid-impaired healing. Corticosteroids suppress inflammation, fibroblast proliferation, and angiogenesis, preventing normal wound repair. BPC-157 cream reversed this impairment in burned mice, restoring wound healing trajectory toward normal.[8] Lazic et al. (2005) extended the findings to corneal wound healing, showing that BPC-157 promoted corneal epithelial defect healing in rats.[9]
The limitation is that all BPC-157 wound healing data comes from animal studies. No randomized controlled trial has tested BPC-157 for wound healing in humans. The peptide is not FDA-approved for any indication. For more on BPC-157's broader evidence base, see BPC-157: The Body Protection Compound and What the Research Shows.
Thymosin Beta-4: Recruiting the Repair Cells
Thymosin beta-4 (TB4) is a 43-amino acid endogenous peptide that plays a central role in actin polymerization, cell migration, and progenitor cell recruitment. It is one of the most abundant peptides in platelets and is released during wound healing.
Malinda et al. (2003) demonstrated that thymosin beta-4 accelerated wound repair in full-thickness dermal wounds in both db/db diabetic mice and aged mice, two models that specifically recapitulate the impaired healing seen in chronic wounds. Treated wounds showed significantly increased wound contracture and collagen deposition compared to vehicle controls. A synthetic peptide containing just the actin-binding domain of thymosin beta-4 (the N-terminal sequence LKKTETQ, known as TB-500) also promoted healing, though the full-length peptide was more effective.
The mechanism involves multiple pathways: TB4 promotes cell migration by regulating actin dynamics, recruits endothelial progenitor cells to the wound site, reduces inflammation by suppressing NF-kB signaling, and stimulates collagen deposition. In the diabetic mouse model, where all of these processes are impaired by hyperglycemia, TB4 was able to restore healing progression.
Granexin (αCT1): The Connexin Mimetic Reaching Phase III
Granexin gel contains αCT1, a 25-amino acid peptide that mimics the carboxyl terminal domain of connexin 43 (Cx43), the most abundant gap junction protein in skin. In chronic wounds, Cx43 is overexpressed at wound edges, creating excessive gap junction communication that paradoxically inhibits cell migration and slows healing.
Montgomery et al. (2021) demonstrated that αCT1 promoted differentiation of a collagen scar matrix toward a more normal tissue architecture, reducing fibrotic scarring while improving the structural quality of wound repair.[10] By modulating Cx43 activity, αCT1 normalizes the wound edge behavior, allowing keratinocytes and fibroblasts to migrate into the wound bed.
Granexin has advanced to phase III clinical trials for diabetic foot ulcers, making it the most clinically advanced peptide-based wound healing therapy. The FDA Breakthrough Therapy designation reflects the unmet medical need: no currently approved drug specifically accelerates chronic wound closure.
Antimicrobial Peptides: Clearing the Infection That Keeps Wounds Stuck
Biofilm infection is present in an estimated 60-80% of chronic wounds. Bacterial biofilms create a physical barrier of extracellular polysaccharides that protects bacteria from antibiotics and the immune system. The persistent infection maintains the wound in a chronic inflammatory state, preventing the transition to proliferative healing.
Adnan et al. (2025) reviewed the role of tripeptides in wound healing and skin regeneration, noting that certain short peptide sequences combine antimicrobial activity with direct wound-healing stimulation.[11] Luckiewicz et al. (2026) explored how cathelicidin LL-37 and ceragenins function in wound healing, documenting LL-37's dual role in both killing bacteria and promoting re-epithelialization.[12]
Da Silva et al. (2025) developed alginate-based hydrogels for sustained antimicrobial peptide delivery to enhance wound healing specifically in diabetic models, addressing the challenge that free peptides are rapidly degraded in the chronic wound environment.[13] The hydrogel format provides sustained release over days, maintaining effective antimicrobial concentrations without repeated application.
For more on antimicrobial peptides in wound care, see Antimicrobial Peptides in Wound Care: Fighting Infection at the Source. For the diabetic wound context specifically, see Diabetic Wound Healing: Where Peptide Research Offers Hope.
The Clinical Reality Gap
The distance between preclinical promise and clinical availability remains the central challenge for peptide wound therapies. GHK-Cu has wound healing data dating to 1988 but no approved wound healing product. BPC-157 has consistent animal data across multiple wound types but zero human trials for wound healing. Thymosin beta-4 showed efficacy in diabetic and aged mouse models but stalled in clinical development.
Granexin is the exception, with a clear regulatory pathway and phase III data forthcoming. Its connexin 43 mechanism is specific and well-characterized, the peptide is applied topically (avoiding systemic exposure concerns), and the unmet need in diabetic foot ulcers provides a favorable regulatory environment.
The next generation of peptide wound therapies combines multiple functions. Hydrogels loaded with antimicrobial peptides plus pro-healing signals address both infection and stalled biology simultaneously. Food-derived bioactive peptides with antioxidant and collagen-stimulating properties offer a lower-cost alternative to synthetic peptides. The field is moving toward multifunctional peptide systems rather than single-peptide, single-mechanism approaches.
The Bottom Line
Chronic wounds fail because the healing cascade stalls in prolonged inflammation, often compounded by biofilm infection. Peptide-based therapies target this stalled biology at multiple points: GHK-Cu stimulates collagen synthesis and extracellular matrix formation, BPC-157 promotes angiogenesis even under corticosteroid impairment, thymosin beta-4 recruits progenitor cells and restores healing in diabetic models, and antimicrobial peptides clear biofilm infections while directly promoting re-epithelialization. Granexin (αCT1), a connexin 43 mimetic peptide in phase III trials for diabetic foot ulcers, is closest to market. The gap between animal evidence and human approval remains wide for most wound-healing peptides.